Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule

Toyoshi Inoguchi; Noriyuki Sonoda; Yasutaka Maeda

doi:10.1007/s13340-016-0288-5

Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule

Toyoshi Inoguchi, Noriyuki Sonoda, Yasutaka Maeda

内分泌代謝・糖尿病内科

研究成果: ジャーナルへの寄稿 › 編集 › 査読

20 被引用数 (Scopus)

本文言語	英語
ページ（範囲）	338-341
ページ数	4
ジャーナル	Diabetology International
巻	7
号	4
DOI	https://doi.org/10.1007/s13340-016-0288-5
出版ステータス	出版済み - 12月 1 2016

!!!All Science Journal Classification (ASJC) codes

内科学
内分泌学、糖尿病および代謝内科学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1007/s13340-016-0288-5

他のファイルとリンク

引用スタイル

@article{2258538262584fe8b1e5907383c96268,

title = "Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule",

author = "Toyoshi Inoguchi and Noriyuki Sonoda and Yasutaka Maeda",

note = "Funding Information: T. Inoguchi received speaker honoraria from Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Sanofi K.K., Astellas Pharma Inc., Kowa Pharmaceutical Co. Ltd., Novartis Pharma K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Co. Ltd., Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd. N. Sonoda received speaker honoraria from Takeda Pharmaceutical Co. Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation. T. Inoguchi received scholarship grants from Dainippon Sumitomo Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Co. Ltd. Y. Maeda has no conflict of interest.",

year = "2016",

month = dec,

day = "1",

doi = "10.1007/s13340-016-0288-5",

language = "English",

volume = "7",

pages = "338--341",

journal = "Diabetology International",

issn = "2190-1678",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes

T2 - a new aspect on old molecule

AU - Inoguchi, Toyoshi

AU - Sonoda, Noriyuki

AU - Maeda, Yasutaka

N1 - Funding Information: T. Inoguchi received speaker honoraria from Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Sanofi K.K., Astellas Pharma Inc., Kowa Pharmaceutical Co. Ltd., Novartis Pharma K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Co. Ltd., Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd. N. Sonoda received speaker honoraria from Takeda Pharmaceutical Co. Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation. T. Inoguchi received scholarship grants from Dainippon Sumitomo Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Co. Ltd. Y. Maeda has no conflict of interest.

PY - 2016/12/1

Y1 - 2016/12/1

UR - http://www.scopus.com/inward/record.url?scp=85001968633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001968633&partnerID=8YFLogxK

U2 - 10.1007/s13340-016-0288-5

DO - 10.1007/s13340-016-0288-5

M3 - Editorial

AN - SCOPUS:85001968633

VL - 7

SP - 338

EP - 341

JO - Diabetology International

JF - Diabetology International

SN - 2190-1678

IS - 4

ER -